에 대한 최신 뉴스 Pharming (NASDAQ:PHAR) 주식

PHARMING GROUP NV - ADR

Pharming

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming Group

PHARMARON BEIJING U/ADR by PHARMARON BEIJING CO LTD.

PHARNEXT by Pharnext

PHarol SGPS SA

PharmChem Inc

PHARMA FOODS INTL CO by Pharma Foods International Co., Ltd.

Pharma Foods International Co Ltd

Pharma Mar SA

PHARM-BIO SERV INC by Pharma-Bio Serv, Inc.

Pharma-Bio Serv Inc

PharmaCielo Ltd

PHARMACOM BIOVET INC by PharmaCom BioVet, Inc.

PharmaCom BioVet Inc

PharmaCyte Biotech Inc

PHARMAROTH LABS INC by PharmaRoth Labs, Inc.

PharmaRoth Labs Inc

PHARMATHER HLDGS LTD by PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd

Pharmadrug Inc

Pharmagen Inc

PHARMAGREEN BIOTECH INC by Pharmagreen Biotech Inc.

Pharmagreen Biotech Inc

Pharmala Biotech Holdings Inc

PHARMALA BIOTECH HLDG INC by PharmAla Biotech Holdings Inc.

PHARMARON BEIJING CO LTD by PHARMARON BEIJING CO LTD.

Pharmaron Beijing Co Ltd

PHARMING GROUP NV ORD by Pharming Group NV

Pharnext SA

Pharos Energy PLC

Pharvaris NV

News

Management

Press Releases

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming Group to participate in February investor conference

Pharming Group to report fourth quarter and full year 2024 financial results on March 13

Pharming Group to participate in March investor conference

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Earnings

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

General

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

Pharming Group reports first quarter 2025 financial results and provides business update

PHAR

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Pharming

뉴스

에 대한 최신 뉴스 Pharming (NASDAQ:PHAR) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌